News

Bioterrorism Response Hampered by Profit

By Paul Kerstein

August 08, 2005CSO — In the last five years, the number of drugs, tools and vaccines available to combat bioterrorism has jumped from one to two because there was no money to be made. The Washington Post reports that despite promises from the drug industry and the passage of a $5.6 billion Project BioShield bill to speed development of products, the nation is hardly better off than it was in 2000. Senators are promoting legislation again that would grant incentives to companies to meet biodefense needs. However, one of the key incentives, extending patent protection for 18 additional months, has started sharp protests.  Opponents say the extension is a giveaway that would keep costs too high for too long, helping the pharmaceutical industry more than average Americans. Read more.

RESOURCE CENTER
Loading...
VIRTUAL CONFERENCE
Data Center Directions Virtual Conference

Data Center VCAttend this free, 100% online event exploring tools and techniques for making your data center deliver for today and tomorrow.

» Learn more and register here

WEBCAST
Safeguarding the New Currency of Business

PricewaterhouseCoopersWatch this webcast to learn how your organization can leverage PricewaterhouseCoopers' Global Information Security Survey 2008, the world's largest survey on privacy and infosec practices.

» View the webcast

Featured Sponsors